Zeftera (ceftobiprole medocaril; Basilea Pharmaceutica) is a novel intravenous broad-spectrum fifth-generation cephalosporin. Upon intravenous administration, ceftobiprole medocaril is rapidly converted to the active drug, ceftobiprole, in the plasma. The drug’s mechanism of action stems from its ability to bind to different types of penicillin-binding proteins found in both Gram-negative and Gram-positive bacteria. Upon binding to such proteins, the drug exhibits its bactericidal activity through inhibiting transpeptidation, and the formation of the bacterial cell wall, leading ultimately to cell lysis and death. Zeftera demonstrated in vitro activity against a broad spectrum of bacterial pathogens, including some drug-resistant Gram-positive strains such as methicillin-resistant Staphylococcus aureus, vancomycin resistant Staphylococcus aureus, penicillin-resistant Streptococcus pneumonia, and ceftriaxone-resistant Streptococcus pneumonia.
Zeftera (ceftobiprole medocaril; Basilea Pharmaceutica) has exhibited a rather broad antibacterial spectrum that includes a number of pathogens with clinical relevance in respiratory infections such as Pseudomonas aeruginosa, methicillin-resistant Staphylococcus aureus (MRSA), as well as the multidrug-resistant Streptococcus pneumonia. Datamonitor Healthcare identifies Zeftera’s antibacterial efficacy as a factor enhancing its clinical attractiveness in the management of community-acquired pneumonia (CAP). However, the drug will face stiff competition from its preceding fifth-generation cephalosporin competitor, Teflaro (ceftaroline fosamil; Actavis/AstraZeneca/Dainippon Sumitomo Pharma). Basilea Pharmaceutica would therefore benefit from collaborating with partners possessing more resources and experience in the antibacterials market.
This is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.